Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Repro-Med Systems Inc Market Cap
The Repro-Med Systems Inc (KRMD) share price is expected to increase by 9.41% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered KRMD. Price targets range from $3.5 at the low end to $5 at the high end. The current analyst consensus for KRMD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Repro-Med Systems Inc has a total of 5 Wall St Analyst ratings. There are 5 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Repro-Med Systems Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of KRMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Chase Knickerbocker Craig-Hallum | Buy | $5 | Maintains | Nov 14, 2024 |
| Caitlin Cronin Canaccord Genuity | Buy | $4 | Maintains | Nov 14, 2024 |
| Jason Bednar Piper Sandler | Overweight | $3.5 | Maintains | Nov 14, 2024 |
| Jason Bednar Piper Sandler | Overweight | $3 | Maintains | Aug 8, 2024 |
| William Woods B. Riley Securities | Buy | $4 | Reiterates | Mar 14, 2024 |
| Caitlin Cronin Canaccord Genuity | Buy | $3 | Reiterates | Dec 7, 2023 |
| Neil Chatterji B. Riley Securities | Buy | $4.5 | Initiates | Sep 7, 2023 |
| Frank Takkinen Lake Street | Buy | $4 | Initiates | Sep 7, 2023 |
| Jason Bednar Piper Sandler | Overweight | $3 | Maintains | Aug 3, 2023 |
| Jason Bednar Piper Sandler | Overweight | $4.5 | Maintains | Jan 6, 2023 |
| Jason Bednar Piper Sandler | Overweight | $3.5 | Upgrade | Nov 10, 2022 |
| Kyle Rose Canaccord Genuity | Buy | $4 | Upgrade | Nov 10, 2022 |
| Matthew O'Brien Piper Sandler | Neutral | $4.5 | Downgrade | Jan 26, 2021 |
| Kyle Rose Canaccord Genuity | Hold | $5 | Downgrade | Jan 26, 2021 |
Canaccord Genuity | Buy | $10 | Maintains | Nov 5, 2020 |
Canaccord Genuity | Buy | Initiates | Jul 16, 2020 | |
Piper Sandler | Overweight | Initiates | Jun 24, 2020 |
When did it IPO
N/A
Staff Count
82
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Ms. Linda M. Tharby
Market Cap
$180.1M
In 2023, KRMD generated $28.5M in revenue, which was a increase of 2.23% from the previous year. This can be seen as a signal that KRMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KORU Medical Systems (NASDAQ: KRMD) will present at Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024, focusing on its large volume subcutaneous infusion solutions.
Why It Matters - KORU Medical's participation in a major healthcare conference could enhance visibility, attract investor interest, and potentially influence stock performance based on future announcements or market reception.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - KORU Medical Systems, Inc. (KRMD) held its Q3 2024 earnings call, discussing financial performance and business developments. Further details can be found in the transcript.
Why It Matters - KORU Medical's Q3 2024 earnings reveal financial performance and strategic direction, impacting stock valuation and investor sentiment regarding future growth potential.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KORU Medical Systems (NASDAQ: KRMD) reported Q3 2024 net revenues of $8 million and raised its full-year revenue, gross margin, and cash guidance.
Why It Matters - KORU Medical's strong Q3 results and raised guidance indicate robust growth potential, enhancing investor confidence and possibly boosting stock performance.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - KORU Medical Systems Inc. (KRMD) reported a quarterly loss of $0.03 per share, matching the Zacks Consensus Estimate and unchanged from the previous year.
Why It Matters - KORU Medical's consistent quarterly loss signals stability but lacks improvement, indicating potential challenges in growth and profitability that may affect investor sentiment.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KORU Medical Systems (NASDAQ: KRMD) will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 15, 2023, showcasing its subcutaneous infusion solutions.
Why It Matters - KORU Medical's participation in investor conferences can enhance visibility, attract potential investors, and signal confidence in its growth strategy, impacting stock performance.
Wed, 06 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - KORU Medical Systems reports solid revenue growth and aims for cash flow breakeven in Q4. The FREEDOM system boosts recurring revenue, with international sales up 46% and novel therapies in Phase 3 trials.
Why It Matters - KORU Medical's revenue growth, potential cash flow breakeven, and advancements in the FREEDOM system highlight strong market prospects, enhancing investor confidence in future returns.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
